Nuvalent
patient journey of majority are advanced metastatic at diagnosis of care sales no clear standard of care and are approved line agnostic in addition to options is included in guidelines as an option following included in guidelines as an alternative option patients may consider clinical trials or chemotherapy i key brain penetrance activity in experienced patients limitations present with brain metastases at diagnosis has been studied in patients with prior and no prior i of patients progressing on have brain metastases with of treatment limiting off target adverse events coverage of resistance mutations of patients progressing on have resistance mutation adverse events associated with inhibition observed in of patients receiving sources a nat rev jordan cancer discovery a sales and forecasts accessed guidelines for version i and lung cancer precision prescribing information cocco nat rev shaw a illustrative image | Nuvalent
Company
Deck Type
Sector
Industry
Deck date
January 2024
Slide
27 of 41
Similar slides by Nuvalent
See diffirences between slides (animation)
Investor Presentation
April 2024
patient journey illustrative image of majority are advanced metastatic at diagnosis standard of care no clear standard of care sales and are approved line agnostic included in guidelines as an alternative option in addition to options is included in guidelines as an option following patients may consider clinical trials or chemotherapy i key brain penetrance activity in experienced patients limitations present with brain metastases at diagnosis of patients progressing on have brain metastases has been studied in patients with prior and no prior i with of treatment limiting off target adverse events coverage of resistance mutations of patients progressing on have resistance mutation adverse events associated with inhibition observed in of patients receiving guidelines for version i and lung cancer precision prescribing information cocco nat rev shaw a | Nuvalent
Investor Presentation
February 2024
patient journey of majority are advanced metastatic at diagnosis standard of care sales no clear standard of care and are approved line agnostic included in guidelines as an alternative option in addition to options is included in guidelines as an option following patients may consider clinical trials or chemotherapy i key limitations brain penetrance activity in experienced patients present with brain metastases at diagnosis of patients progressing on have brain metastases has been studied in patients with prior and no prior i with of treatment limiting off target adverse events coverage of resistance mutations of patients progressing on have resistance mutation adverse events associated with inhibition observed in of patients receiving sources a nat rev jordan guidelines for version i and lung cancer information cocco nat rev shaw a cancer discovery a year end earnings reports precision prescribing illustrative image | Nuvalent
Investor Presentation
January 2024
patient journey of majority are advanced metastatic at diagnosis of care sales no clear standard of care and are approved line agnostic in addition to options is included in guidelines as an option following included in guidelines as an alternative option patients may consider clinical trials or chemotherapy i key brain penetrance activity in experienced patients limitations present with brain metastases at diagnosis has been studied in patients with prior and no prior i of patients progressing on have brain metastases with of treatment limiting off target adverse events coverage of resistance mutations of patients progressing on have resistance mutation adverse events associated with inhibition observed in of patients receiving sources a nat rev jordan cancer discovery a sales and forecasts accessed guidelines for version i and lung cancer precision prescribing information cocco nat rev shaw a illustrative image | Nuvalent
Related slides by other companies
Oculis
Investor Presentation
April 2024
despite new treatment options patient satisfaction remains a challenge era no | Oculis
AstraZeneca
Investor Day
June 2021
changing treatment expectations in continuing to push the boundaries of science and patient care | AstraZeneca
Imara
Mergers and Acquisitions
October 2022
significant need remains for more treatment options for | Imara
Imara
Mergers and Acquisitions
October 2022
despite great advances a significant need remains for better treatment options for chronic myeloid leukemia | Imara
Other recent decks by Nuvalent
See all presentations (10 decks)
Investor Presentation
April 2024
Investor Presentation
February 2024
Investor Presentation
January 2024
Investor Presentation
November 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io